CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)

Phase 2

Completed

• Conditions: Abdominal Aortic Aneurysm
• Interventions: Drug: CRD007; Drug: CRD007 matching placebo

• Registration Number: NCT01354184
• Lead Sponsor: RSPR Pharma AB

Brief Summary

This is an investigation of the efficacy and safety of CRD007 compared to placebo in the treatment of patients with abdominal aortic aneurysm.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-05-13
• Study First Submitted QC: 2011-05-13
• Study First Posted: 2011-05-16
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-05
• Last Update Posted: 2012-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Infra-renal abdominal aortic aneurysm

Exclusion Criteria

• Previous infra-renal aortic surgery
• Known diabetes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
CRD007 40 mg tablet	CRD007	-
CRD007 matching placebo tablet	CRD007 matching placebo	-
CRD007 10 mg tablet	CRD007	-
CRD007 25 mg tablet	CRD007	-

Trial Locations

Locations (15)

Aalborg Hospital, Department of Vascular Surgery V; 🇩🇰 Aalborg, Denmark

Aarhus Universitetshospital Skejby, Hjerte-Lunge-Kar kir. afd. T; 🇩🇰 Aarhus, Denmark

Rigshospitalet, Karkirurgisk afdeling RK 3111; 🇩🇰 Copenhagen, Denmark

Sygehus Lillebælt, Karkirurgisk Forskningsenhed; 🇩🇰 Kolding, Denmark

Regionshospitalet Viborg, Karkiurgisk Forskningssektion; 🇩🇰 Viborg, Denmark

Borås Hospital, Department of Surgery; 🇸🇪 Borås, Sweden

Mälarsjukhuset, Team Kärl Kir. Klin.; 🇸🇪 Eskilstuna, Sweden

Sahlgrenska Universitetssjukhuset; 🇸🇪 Göteborg, Sweden

Skånes Universitets Sjukhus, Institution of Surgical Science; 🇸🇪 Malmo, Sweden

Universitetssjukhuset Örebro, Kirurgkliniken, Kärlsektionen; 🇸🇪 Orebro, Sweden

Scroll for more (5 remaining)